Overview
Sweden medical technology firm's Q1 net sales rose yr/yr, marking its strongest first quarter
Q1 loss after financial items narrowed compared to prior year
Company surpassed 50 installed systems globally during the quarter
Outlook
Company prioritizes expansion in North America and Central Europe through sales staff training
ChemoTech expects recurring revenues from treatment kits to improve predictability and long-term value
Company maintains focus on disciplined execution, operational efficiency, and sustainable growth
Result Drivers
SALES PROCESS IMPROVEMENTS - Co said operational improvements and strengthened sales processes, especially in the U.S., contributed to more reliable revenue generation
ANIMAL CARE ADOPTION - Increased adoption of vetIQure and Tumour Specific Electroporation (TSE) among clinics supported revenue growth
RECURRING REVENUE - Higher share of revenue from recurring treatment kit sales improved predictability and long-term value creation
Company press release:
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
SEK 2.80 mln
Q1 EPS
-SEK 0.06
Q1 Operating Cash Flow
-SEK 1.14 mln
Analyst Coverage
Wall Street's median 12-month price target for Scandinavian ChemoTech AB is SEK6.30, about 58.7% above its April 27 closing price of SEK3.97
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .